MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Introduction: The multiple biological responses to estrogens are mainly mediated by the classical estrogen receptors ERα and ERβ, which act as ligand-activated transcription factors. ERα exerts a main role in the development of breast cancer; therefore, the ER antagonist tamoxifen has been widely used although its effectiveness is limited by de novo and acquired resistance. Recently, GPR30/GPER, a member of the seven-transmembrane G protein-coupled receptor family, has been implicated in mediating the effects of estrogens in various normal and cancer cells. In particular, GPER triggered gene expression and proliferative responses induced by estrogens and even ER antagonists in hormone-sensitive tumor cells. Likewise, additional ER ligands showed the ability to bind to GPER eliciting promiscuous and, in some cases, opposite actions through the two receptors. We synthesized a novel compound (ethyl 3-[5-(2-ethoxycarbonyl-1-methylvinyloxy)-1-methyl-1H-indol-3-yl]but-2-enoate), referred to as MIBE, and investigated its properties elicited through ERα and GPER in breast cancer cells. Methods: Molecular modeling, binding experiments and functional assays were performed in order to evaluate the biological action exerted by MIBE through ERα and GPER in MCF7 and SkBr3 breast cancer cells. Results: MIBE displayed the ability to act as an antagonist ligand for ERα and GPER as it elicited inhibitory effects on gene transcription and growth effects by binding to both receptors in breast cancer cells. Moreover, GPER was required for epidermal growth factor receptor (EGFR) and ERK activation by EGF as ascertained by using MIBE and performing gene silencing experiments. Conclusions: Our findings provide novel insights on the functional cross-talk between GPER and EGFR signaling. Furthermore, the exclusive antagonistic activity exerted by MIBE on ERα and GPER could represent an innovative pharmacological approach targeting breast carcinomas which express one or both receptors at the beginning and/or during tumor progression. Hence, the simultaneous inhibition of both ERα and GPER may guarantee major therapeutic benefits in respect to the use of a selective estrogen receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302
In vitro molecular mechanisms of bisphenol A action.
Wetherill, Y. B., Akingbemi, B. T., Kanno, J., McLachlan, J. A., Nadal, A., Sonnenschein, C., Watson, C. S., Zoeller, R. T., & Belcher, S. M. (2007) · Reproductive Toxicology · doi:10.1016/j.reprotox.2007.05.010 · Cited by 920 · cited 1×
“For instance, the phytoestrogen genistein and the xenoestrogen bisphenol A, which exert estrogen-like activities binding to and activating ERa [9,59], displayed the ability to bind to and activate GPER signaling [9,27,60].”
BackgroundG protein-coupled receptors: novel targets for drug discovery in cancer
Lappano, R., & Maggiolini, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3320 · Cited by 717
Self-citationThe unfolding stories of GPR30, a new membrane-bound estrogen receptor
Maggiolini, M., & Picard, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0242 · Cited by 360 · cited 6×
“The rapid responses to estrogenic signals mediated by GPER regulate a typical gene signature, as revealed in previous studies, including a microarray analysis [7,24].”
BackgroundMethodInfluentialSelf-citationMechanisms of estrogen signaling and gene expression via GPR30
Prossnitz, E. R., & Maggiolini, M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.03.026 · Cited by 346
Self-citation
Cited by
Estrogen biology: New insights into GPER function and clinical opportunities
Prossnitz, E. R., & Barton, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.02.002 · Cited by 400
Prossnitz, E. R., & Arterburn, J. B. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009712 · Cited by 258
The G protein-coupled oestrogen receptor GPER in health and disease: an update
Prossnitz, E. R., & Barton, M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00822-7 · Cited by 231
Copper activates HIF-1α/GPER/VEGF signalling in cancer cells
Rigiracciolo, D. C., Scarpelli, A., Lappano, R., Pisano, A., Santolla, M. F., De Marco, P., Cirillo, F., Cappello, A. R., Dolce, V., Belfiore, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5779 · Cited by 184
Self-citationThe lauric acid-activated signaling prompts apoptosis in cancer cells
Lappano, R., Sebastiani, A., Cirillo, F., Rigiracciolo, D. C., Galli, G. R., Curcio, R., Malaguarnera, R., Belfiore, A., Cappello, A. R., & Maggiolini, M. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.63 · Cited by 169
Self-citation
Metadata
- Authors
- Lappano, R., Santolla, M. F., Pupo, M., Sinicropi, M. S., Caruso, A., Rosano, C., & Maggiolini, M.
- Venue
- Breast Cancer Research
- Published
- 2012-01-17
- Volume
- 14
- Issue
- 1
- Pages
- R12-R12
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2146012616
- Cited by
- 94
- References
- 5
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.